Cargando…

Cooperative Genomic Lesions in HRAS-Mutant Cancers Predict Resistance to Farnesyltransferase Inhibitors

The clinical development of farnesyltransferase inhibitors (FTI) for HRAS-mutant tumors showed mixed responses dependent on cancer type. Co-occurring mutations may affect response. We aimed to uncover cooperative genetic events specific to HRAS-mutant tumors and study their effect on FTI sensitivity...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nigam, Aradhya, Krishnamoorthy, Gnana, Chatila, Walid, Berman, Katherine, Saqcena, Mahesh, Walch, Henry, Ho, Alan, Schultz, Nikolaus, Fagin, James, Untch, Brian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Journal Experts 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10371077/ https://www.ncbi.nlm.nih.gov/pubmed/37503077 http://dx.doi.org/10.21203/rs.3.rs-3154719/v1

Ejemplares similares

Transformation by Hras(G12V) is Consistently Associated with Mutant Allele Copy Gains and is Reversed by Farnesyl Transferase Inhibition
por: Chen, Xu, et al.
Publicado: (2013)

Co-inhibition of SMAD and MAPK signaling enhances (124)I uptake in BRAF-mutant thyroid cancers
por: Luckett, Kathleen A, et al.
Publicado: (2021)

Yap governs a lineage-specific neuregulin1 pathway-driven adaptive resistance to RAF kinase inhibitors
por: Garcia-Rendueles, Maria E. R., et al.
Publicado: (2022)

Mutant HRAS as novel target for MEK and mTOR inhibitors
por: Kiessling, Michael K., et al.
Publicado: (2015)

Targeting farnesylation as a novel therapeutic approach in HRAS-mutant rhabdomyosarcoma
por: Odeniyide, Patience, et al.
Publicado: (2022)

Elderly Former Smoker with HRAS Mutant Non–Small-Cell Lung Cancer
por: Cathcart-Rake, Elizabeth, et al.
Publicado: (2014)

Correction: Targeting farnesylation as a novel therapeutic approach in HRAS-mutant rhabdomyosarcoma
por: Odeniyide, Patience, et al.
Publicado: (2022)

Bacteria Are New Targets for Inhibitors of Human Farnesyltransferase
por: Weber, Lea, et al.
Publicado: (2021)

New targets for therapy in breast cancer: Farnesyltransferase inhibitors
por: Head, Julia, et al.
Publicado: (2004)

Engineering Protein Farnesyltransferase for Enzymatic Protein Labeling Applications
por: Dozier, Jonathan K., et al.
Publicado: (2014)

Effect of farnesyltransferase inhibitor on the function of mitochondria of Plasmodium falciparum
por: Ha, Young Ran, et al.
Publicado: (2012)

An overview on natural farnesyltransferase inhibitors for efficient cancer therapy
por: Dai, Xiaohan, et al.
Publicado: (2020)

Effect of farnesyltransferase inhibitors on SARS-CoV-2
por: Weber, Lea, et al.
Publicado: (2023)

Analyzing the postulated inhibitory effect of Manumycin A on farnesyltransferase
por: Hagemann, Anna, et al.
Publicado: (2022)

Argonaute 2 modulates EGFR–RAS signaling to promote mutant HRAS and NRAS-driven malignancies
por: Siebenaler, Ronald F, et al.
Publicado: (2022)

Assessing the efficacy of protein farnesyltransferase inhibitors in mouse models of progeria
por: Yang, Shao H., et al.
Publicado: (2010)

Effect of Farnesyltransferase Inhibitor R115777 on Mitochondria of Plasmodium falciparum
por: Ha, Young Ran, et al.
Publicado: (2015)

Bioactivity of Farnesyltransferase Inhibitors Against Entamoeba histolytica and Schistosoma mansoni
por: Probst, Alexandra, et al.
Publicado: (2019)

Roles of Farnesyl-Diphosphate Farnesyltransferase 1 in Tumour and Tumour Microenvironments
por: Ha, Nguyen Thi, et al.
Publicado: (2020)

Blocking anaplerotic entry of glutamine to TCA cycle sensitizes K-Ras mutant cancer cells to cytotoxic drugs
por: Saqcena, Mahesh, et al.
Publicado: (2014)

Inhibition of oncogene-induced inflammatory chemokines using a farnesyltransferase inhibitor
por: DeGeorge, Katharine C, et al.
Publicado: (2008)

New targeted therapies in myelodysplastic syndrome: the role of farnesyltransferase and proteasome inhibitors
por: Gonçalves, A Cristina, et al.
Publicado: (2010)

In Vitro Apoptotic Effects of Farnesyltransferase blockade in Acute Myeloid Leukemia Cells
por: Giudice, V, et al.
Publicado: (2016)

A Farnesyltransferase Acts to Inhibit Ectopic Neurite Formation in C. elegans
por: Carr, David, et al.
Publicado: (2016)

MALDI-MS Analysis of Peptide Libraries Expands the Scope of Substrates for Farnesyltransferase
por: Schey, Garrett L., et al.
Publicado: (2021)

Phenothiazine- and Carbazole-Cyanochalcones as Dual Inhibitors of Tubulin Polymerization and Human Farnesyltransferase
por: Zubaș, Andreea, et al.
Publicado: (2023)

In vitro antifungal activity of farnesyltransferase inhibitors against clinical isolates of Aspergillus and Candida
por: Qiao, Jianjun, et al.
Publicado: (2013)

Inhibition of Farnesyltransferase Potentiates NOTCH-Targeted Therapy against Glioblastoma Stem Cells
por: Ma, Yufang, et al.
Publicado: (2017)

Mechanism of the Exchange Reaction in HRAS from Multiscale Modeling
por: Kapoor, Abhijeet, et al.
Publicado: (2014)

HRAS mutation prevalence and associated expression patterns in pheochromocytoma
por: Stenman, Adam, et al.
Publicado: (2016)

Phacomatosis pigmentokeratotica and precocious puberty associated with HRAS mutation
por: Martin, R.J., et al.
Publicado: (2017)

Comparative MD simulations and advanced analytics based studies on wild-type and hot-spot mutant A59G HRas
por: Sharma, Neeru, et al.
Publicado: (2020)

Phase II study of the farnesyltransferase inhibitor R115777 in advanced melanoma (CALGB 500104)
por: Gajewski, Thomas F, et al.
Publicado: (2012)

Preventing farnesylation of the dynein adaptor Spindly contributes to the mitotic defects caused by farnesyltransferase inhibitors
por: Holland, Andrew J., et al.
Publicado: (2015)

Virtual Lead Identification of Farnesyltransferase Inhibitors Based on Ligand and Structure-Based Pharmacophore Techniques
por: Al-Balas, Qosay A., et al.
Publicado: (2013)

Cytolytic toxin production by Staphylococcus aureus is dependent upon the activity of the protoheme IX farnesyltransferase
por: Stevens, Emily, et al.
Publicado: (2017)

Farnesyltransferase inhibitor LNK-754 attenuates axonal dystrophy and reduces amyloid pathology in mice
por: Cuddy, Leah K., et al.
Publicado: (2022)

MTH1 expression is required for effective transformation by oncogenic HRAS
por: Giribaldi, Maria G., et al.
Publicado: (2015)

The Prognostic Value of HRAS mRNA Expression in Cutaneous Melanoma
por: Wan, Xiaohua, et al.
Publicado: (2017)

Analysis of FGFR3 and HRAS genes in patients with bladder cancer
por: Homami, Ameneh, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_7c48m1e195ikdv22boo45ul88a